利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.031 秒)

    Diagnostic method for Alzheimer's disease
    41.
    发明授权
    Diagnostic method for Alzheimer's disease 失效
    阿尔茨海默病的诊断方法

    公开(公告)号：US06300085B1

    公开(公告)日：2001-10-09

    申请号：US08809646

    申请日：1997-07-18

    申请人： Daniel L. Alkon

    发明人： Daniel L. Alkon

    IPC分类号： G01N3353

    CPC分类号： C07K14/4711 ,  C07K16/18 ,  G01N33/5091 ,  G01N33/573 ,  G01N33/6872 ,  G01N33/6896 ,  G01N2333/9121 ,  G01N2800/2821 ,  Y10S436/811

    摘要： The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.

    摘要翻译： 本发明提供了使用人类细胞诊断阿尔茨海默病的方法。 具体来说，一种方法检测来自阿尔茨海默病患者和正常供体的细胞中的钾通道之间的差异，以及响应于已知增加细胞内钙水平的化学物质的阿尔茨海默氏病和正常细胞之间的细胞内钙浓度的差异。 其他方法检测与老年痴呆和正常细胞之间记忆相关的GTP结合Cp20蛋白水平之间的差异。 此外，提供了用于改善阿尔茨海默氏症和非阿尔茨海默病细胞之间评估的诊断指标。

    Diagnostic test for alzheimers disease
    42.
    发明授权
    Diagnostic test for alzheimers disease 失效
    阿尔茨海默病诊断试验

    公开(公告)号：US6107050A

    公开(公告)日：2000-08-22

    申请号：US075725

    申请日：1998-05-11

    申请人： Daniel L. Alkon ,  Antonelle R. Favit ,  Maurizio Grimaldi

    发明人： Daniel L. Alkon ,  Antonelle R. Favit ,  Maurizio Grimaldi

    IPC分类号： C07K14/47 ,  C07K16/18 ,  G01N33/50 ,  G01N33/573 ,  G01N33/68

    CPC分类号： C07K14/4711 ,  C07K16/18 ,  G01N33/5091 ,  G01N33/573 ,  G01N33/6872 ,  G01N33/6896 ,  G01N2333/9121 ,  G01N2800/2821 ,  Y10S436/811

    摘要： The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. Another method utilizes the differential effects of .beta.-amyloid protein on levels of the protein kinase C isoenzymes PKC.alpha. and PKC.gamma. in Alzheimer's and normal cells. Yet another method detects Eu-TTA fluorescence differences between Alzheimer's and normal cells treated with an activator of a receptor-mediated metabolic pathway. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.

    摘要翻译： 本发明提供了使用人类细胞诊断阿尔茨海默病的方法。 具体来说，一种方法检测来自阿尔茨海默病患者和正常供体的细胞中的钾通道之间的差异，以及响应于已知增加细胞内钙水平的化学物质的阿尔茨海默氏病和正常细胞之间的细胞内钙浓度的差异。 其他方法检测与老年痴呆和正常细胞之间记忆相关的GTP结合Cp20蛋白水平之间的差异。 另一种方法利用β-淀粉样蛋白对阿尔茨海默氏症和正常细胞中蛋白激酶C同功酶PKCα和PKCγ水平的差异作用。 另一种方法检测阿尔茨海默氏症与用受体介导的代谢途径的激活剂治疗的正常细胞之间的Eu-TTA荧光差异。 此外，提供了用于改善阿尔茨海默氏症和非阿尔茨海默病细胞之间评估的诊断指标。

    Dynamically stable associative learning neural system with one fixed weight
    45.
    发明授权
    Dynamically stable associative learning neural system with one fixed weight 失效
    动态稳定关联学习神经系统具有一个固定的权重

    公开(公告)号：US5222195A

    公开(公告)日：1993-06-22

    申请号：US864337

    申请日：1992-04-06

    申请人： Daniel L. Alkon ,  Thomas P. Vogl ,  Kim L. Blackwell

    发明人： Daniel L. Alkon ,  Thomas P. Vogl ,  Kim L. Blackwell

    IPC分类号： G06N3/04

    CPC分类号： G06N3/04

    摘要： A dynamically stable associative learning neural network system include a plurality of synapses (122,22-28), a non-linear function circuit (30) and an adaptive weight circuit (150) for adjusting the weight of each synapse based upon the present signal and the prior history of signals applied to the input of the particular synapse and the present signal and the prior history of signals applied to the input of a predetermined set of other collateral synapses. A flow-through neuron circuit (1110) embodiment includes a flow-through synapse (122) having a predetermined fixed weight. A neural network is formed by a set of flow-through neuron circuits connected by flow-through synapses to form separate paths between each input (215) and a corresponding output (245). In one embodiment (200), the neuron network is initialized by setting the adjustable synapses at some value near the minimum weight and setting the flow-through neuron circuits at some arbitrarily high weight. The neural network embodiments are taught by successively application of sets of inputs signals to the input terminals until a dynamic equilibrium is reached.

    摘要翻译： 动态稳定的关联学习神经网络系统包括多个突触（122,22-28），非线性函数电路（30）和自适应加权电路（150），用于根据本信号调整每个突触的重量 以及施加到特定突触的输入和当前信号的信号的先前历史以及施加到预定的一组其他附属突触的输入的信号的先前历史。 流过神经元电路（1110）实施例包括具有预定固定重量的流通突触（122）。 神经网络由一组通过流通突触连接的流通神经元电路形成，以在每个输入（215）和相应的输出（245）之间形成分离的路径。 在一个实施例（200）中，通过将可调节的突触设置在接近最小权重的某个值处来初始化神经元网络，并且将流通神经元电路设置在某种任意高的权重。 神经网络实施例通过将输入信号组连续地应用于输入端来教导，直到达到动态平衡。

    Methods and Compositions for Regenerative Synaptogenesis
    46.
    发明申请
    Methods and Compositions for Regenerative Synaptogenesis 审中-公开

    公开(公告)号：US20190054070A1

    公开(公告)日：2019-02-21

    申请号：US15923277

    申请日：2018-03-16

    申请人： Daniel L. Alkon

    发明人： Daniel L. Alkon

    IPC分类号： A61K31/4155 ,  A61P25/00 ,  A61K31/366 ,  A61K31/454 ,  A61K31/4245 ,  A61K31/7076 ,  A61K31/185

    摘要： Provided herein are uses of pharmaceutically effective amounts of an inhibitor of an arginine methyltransferase alone or in combination with one or more bryostatins to promote regenerative synaptogenesis. Also provided are methods for promoting regenerative synaptogenesis in a patient by administering a pharmaceutically effective amount of an inhibitor of an arginine methyltransferase alone or in combination with a PKC activator to the patient. Likewise, methods are also provided are methods for promoting dendritic maturation in a patient by administering a pharmaceutically effective amount of an inhibitor of an arginine methyltransferase alone or in combination with a PKC activator to the patient, wherein the administration promotes synaptic formation in the hippocampus.

    ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF PROTEIN KINASE C EPSILON (PKC-EPSILON) PROTEIN LEVELS
    49.
    发明申请
    ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF PROTEIN KINASE C EPSILON (PKC-EPSILON) PROTEIN LEVELS 审中-公开
    蛋白激酶C蛋白激酶（PKC-EPSILON）蛋白水平的ALZHEIMER疾病特异性改变

    公开(公告)号：US20140038186A1

    公开(公告)日：2014-02-06

    申请号：US13580431

    申请日：2011-02-22

    申请人： Tapan Kumar Khan ,  Daniel L. Alkon

    发明人： Tapan Kumar Khan ,  Daniel L. Alkon

    IPC分类号： C12Q1/48 ,  G01N33/573 ,  C12Q1/68

    CPC分类号： C12Q1/485 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/573 ,  G01N33/6896 ,  G01N2333/912 ,  G01N2800/2821

    摘要： The present invention relates to methods of diagnosing Alzheimer's Disease in a human patient by detecting alterations in the ratio of PKC epsilon protein levels in a human patient compared with PKC epsilon levels in a control subject. The Alzheimer's disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's disease and for screening methods for the identification of compounds for treating or preventing Alzheimer's disease. The present invention also provides methods for elevating PKC epsilon protein levels comprising the steps of contacting one or more human cells with an amount of a PKC activator effective to elevate PKC epsilon levels compared to an uncontacted human cell.

    摘要翻译： 本发明涉及通过检测人类患者中PKCε蛋白水平与对照受试者中的PKCε水平相比的变化来诊断人类患者中的阿尔茨海默病的方法。 本文公开的阿尔茨海默病特异性分子生物标志物可用于诊断阿尔茨海默病和用于鉴定用于治疗或预防阿尔茨海默氏病的化合物的筛选方法。 本发明还提供了用于升高PKCε蛋白水平的方法，其包括以下步骤：使一个或多个人细胞与一定量的PKC激活剂相接触，以有效提高PKCε水平与未接触的人细胞相比。

    PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
    50.
    发明申请
    PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS 审中-公开
    PKC激活作为增强sAPPalpha分泌和使用BRYOSTATIN型化合物的感染的手段

    公开(公告)号：US20130072550A1

    公开(公告)日：2013-03-21

    申请号：US13608874

    申请日：2012-09-10

    申请人： Rene Etcheberrigaray ,  Daniel L. Alkon

    发明人： Rene Etcheberrigaray ,  Daniel L. Alkon

    IPC分类号： A61K31/365 ,  A61P25/28 ,  A61P25/00

    CPC分类号： A61K31/7048 ,  A61K31/00 ,  A61K31/365

    摘要： The present disclosure relates to methods of administering compounds for treating conditions associated with amyloid processing such as Alzheimer's Disease. Methods are disclosed comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need in an amount effective to decrease soluble Aβ-40 or Aβ-42, or to lower total amyloid precursor protein (“APP”). Methods are also disclosed further comprising the step of identifying a subject with increased soluble Aβ-40 or Aβ-42 levels, or elevated APP levels compared to a control population.

    摘要翻译： 本公开涉及施用用于治疗与淀粉样蛋白加工如阿尔茨海默病相关的病症的化合物的方法。 公开的方法包括将大环内酯，苯并内酰胺，吡咯烷酮或其组合施用于需要的受试者以有效降低可溶性Aβ-40或A-bgr--42的量或降低总淀粉样蛋白前体蛋白 （APP）。 还公开了进一步包括以下步骤：与对照群体相比，鉴定具有增加的可溶性A-Bgr--40或A＆bgr--42水平或升高的APP水平的受试者的步骤。